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Abstract 118 
Context: Low testosterone (T) has been associated with incident metabolic syndrome (MetS), but it 119 
remains unclear if this association is independent of sex hormone binding globulin (SHBG). Estradiol 120 
(E2) may also be associated with MetS, but few studies have investigated this.  121 
Objective: To study the association between baseline sex steroids and the development of incident 122 
MetS and to investigate the influence of SHBG, BMI and insulin resistance on this risk.  123 
Methods: 3369 community-dwelling men aged 40-79 years were recruited for participation in EMAS. 124 
MetS was defined by the updated NCEP ATP III criteria. Testosterone and E2 levels were measured 125 
by liquid and gas chromatography/mass spectrometry respectively. Logistic regression was used to 126 
assess the association between sex steroids and incident MetS.  127 
Results: 1651 men without MetS at baseline were identified. During follow-up 289 men developed 128 
incident MetS, while 1362 men did not develop MetS. Men with lower baseline total T levels were at 129 
higher risk for developing MetS (Odds ratio (OR)=1.72, p˂0.001), even after adjustment for SHBG 130 
(OR=1.43, p=0.001), BMI (OR=1.44, p˂0.001) or HOMA-IR (OR=1.64, p˂0.001). E2 was not 131 
associated with development of MetS (OR=1.04; p=0.56). However, a lower E2/T ratio was associated 132 
with a lower risk of incident MetS (OR=0.38; p˂0.001), even after adjustment for SHBG (OR=0.48; 133 
p˂0.001), BMI (OR=0.60; p=0.001) or HOMA-IR (OR=0.41; p<0.001). 134 
Conclusions: In men, lower T levels, but not E2, are linked with an increased risk of developing 135 
MetS, independent of SHBG, BMI or insulin resistance. A lower E2/T ratio may be protective against 136 
developing MetS. 137 
 138 
 139 
 140 
 141 
 142 
 143 
 144 
 145 
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Introduction 146 
Metabolic syndrome (MetS) describes a cluster of features including abdominal obesity, dyslipidemia, 147 
hypertension and insulin resistance that are associated with an increased risk of developing type 2 148 
diabetes, cardiovascular disease and death (1,2). Moreover, these risks are higher than those associated 149 
with individual components of the syndrome (2). Up to one-quarter to one-third of the adult population 150 
in Europe and the United States can be diagnosed with MetS (1-3), making it an important public 151 
health target for disease prevention.  152 
Both low total testosterone (T) and low sex hormone binding globulin (SHBG) have been associated 153 
with an increased risk of MetS in men (4-9).  However, serum concentrations of total and free T are 154 
strongly linked to SHBG, especially in men with obesity (10). Whether the risk of MetS associated 155 
with low T is independent of SHBG or vice versa, remains unclear.  156 
Furthermore, T is converted to estradiol (E2) by the aromatase enzyme, which is highly expressed in 157 
adipose tissue (11) . A recent experimental study showed that lowering E2 levels in healthy males 158 
increased body fat, independent of T (12). Although both T and E2 are associated with variations in 159 
body composition in men (12,13), the potential impact of E2 and the extent of aromatisation on the 160 
risk for incident MetS has not been investigated prospectively.  161 
 162 
Using data from the European Male Aging Study (EMAS), a prospective study of aging in European 163 
men, we studied the association between baseline sex steroids (T and E2) and the risk of developing 164 
MetS at follow-up and investigated if this association was independent of SHBG, body mass index 165 
(BMI), insulin resistance and body fat measurements. We also assessed whether sex steroids were 166 
associated with change in individual MetS components. 167 
 168 
Methods 169 
Subjects and study design 170 
The prospective study design of EMAS has been described previously (14). From 2003 to 2005, 3369 171 
men aged 40-79 years were recruited from population registers in eight European centres: Manchester, 172 
United Kingdom; Leuven, Belgium; Malmö, Sweden; Tartu, Estonia; Lodz, Poland; Szeged, Hungary; 173 
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Florence, Italy and Santiago de Compostela, Spain. After a median follow-up time of 4.3 years (range 174 
2.95-5.7 years), 2736 men participated in phase 2. From the original cohort, 193 men had died and 440 175 
were lost to follow-up. 150 men were excluded because of known pituitary or testicular disease or 176 
current drug use of medications that could affect pituitary or testicular function or sex steroid 177 
clearance (e.g. GnRH agonists, testosterone, anticonvulsants). Ethical approval for the study was 178 
acquired in accordance with local institutional requirements at each centre. All subjects gave written 179 
informed consent. 180 
 181 
Assessments 182 
At both phases, participants completed a postal questionnaire that included information about general 183 
health (response set: excellent, very good, good, fair or poor), smoking history (current, past or non-184 
smoker) and frequency of alcohol consumption in the previous month (none, less than once a week, 1-185 
2, 3-4, 5-6 or 7 days per week) (14). Current prescription and non-prescription medication use was 186 
recorded. 187 
Height, weight and waist circumference were measured in a standing position. Body weight was 188 
measured to the nearest 0.1 kg using an electronic scale (SECA UK Ltd, Birmingham, UK) and height 189 
to the nearest 1 mm using a stadiometer (Leicester Height Measure, SECA UK Ltd). Waist 190 
circumference was measured using anthropometric tape, and the median of three measurements was 191 
used as the recorded value. Body mass index (BMI) was calculated as body weight (kilograms) 192 
divided by the square of height (meters). Body fat percentage was calculated by the Siri equation, 193 
based on a subject’s average density (body mass divided by body volume) (15). Seated blood pressure 194 
(Omron 500I, Omron Healthcare (UK) Ltd, Milton Keynes, UK) was recorded after a 5 min rest 195 
period. Physical function was assessed via gait speed in a timed 50-feet walk (16). 196 
 197 
Laboratory measurements 198 
At both phases, a single fasting morning (before 10.00 h) venous blood sample was obtained from 199 
each subject. 200 
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Total T was measured by liquid chromatography-tandem mass spectrometry as described previously  201 
(17). The lower limit of quantification (LOQ) was 0.25 nmol/l. The coefficients of variation were less 202 
than 10% within runs and between runs. Measurement of total E2 was carried out by gas 203 
chromatography-tandem mass spectrometry as described previously (18). The LOQ for E2 was 7.34 204 
pmol/l. The coefficients of variation were less than 5% within runs and between runs. The E2/T ratio, 205 
a measure of aromatisation, was calculated by dividing total E2 concentration in nmol/L by total T 206 
concentration in nmol/L. SHBG was measured by the Modular E170 platform 207 
electrochemiluminescence immunoassay (Roche Diagnostics, Mannheim, Germany). Free T and E2 208 
levels were calculated from total hormone levels, SHBG, and individual albumin concentrations by the 209 
Vermeulen formula (19). 210 
Albumin, glucose, cholesterol and triglyceride measurements were assessed at the local health care 211 
facility. Insulin was assayed using quimioluminiscence (University of Santiago de Compostela). 212 
Insulin resistance was calculated using the homeostasis model assessment of insulin resistance 213 
(HOMA-IR) (20).  214 
 215 
Dual energy X-ray absorptiometry  216 
In the Leuven and Manchester cohort, body composition at baseline was assessed by dual energy X-217 
ray absorptiometry (DXA) (QDR 4500A Discovery scanner, Hologic  Inc, Bedford, MA, USA), as 218 
described elsewhere (21). Percentage body fat and trunk fat was calculated by dividing body fat mass 219 
or trunk fat mass by total body mass, multiplied by 100.  220 
 221 
Definition of the metabolic syndrome and its components 222 
MetS was defined according to the updated NCEP ATPIII criteria (22). Subjects were classified with 223 
MetS when three or more of the following criteria were present: waist circumference ≥ 102 cm, 224 
triglyceride level ≥ 1.7 mmol/l (150 mg/dl), HDL cholesterol levels < 1.03 mmol/l (40 mg/dl), blood 225 
pressure ≥ 130/85 mmHg and a fasting glucose level ≥ 5.6 mmol/l (100 mg/dl).  226 
Subjects on antihypertensive drugs or antidiabetic drugs were classified positive for the blood pressure 227 
or glucose criterion respectively. Subjects without MetS at baseline, but who developed MetS during 228 
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follow-up, were classified as ‘Incident MetS’. Subjects without MetS at either time point were 229 
classified as ‘No MetS’. 230 
Subjects with missing data were excluded if MetS could not be determined with certainty. For 231 
instance, a subject with four positive MetS criteria and one missing was classified as having MetS. 232 
However, in a subject with two positive, two negative and one missing MetS criterion, the MetS status 233 
could not be determined with certainty, and these subjects were excluded from the analysis.  234 
 235 
Statistical analysis 236 
Descriptive statistics were used to characterise subjects at baseline. Smoking status was categorised as 237 
current versus never and ex-smokers (referent). Alcohol intake was stratified as less than four days per 238 
week (referent) versus five or more days per week. General health was defined as poor/fair versus 239 
good/very good/excellent (referent). To assess associations with decreasing sex steroid and SHBG 240 
levels, these variables were multiplied by -1 and converted to standardised z-scores. Baseline total T, 241 
free T and SHBG were also categorized into quintiles, with the middle quintile as referent. 242 
Logistic regression analysis was used to determine associations between baseline sex steroids 243 
(predictor) and incident MetS (outcome). Results were expressed as standardised odds ratios (OR) 244 
with 95% confidence intervals (CI).  The analysis was performed unadjusted, with adjustments for 245 
age, study centre, smoking status, alcohol intake, physical activity and general health, and with 246 
additional adjustments for SHBG or total T as indicated. As both insulin sensitivity and obesity can 247 
influence T and SHBG levels, we subsequently adjusted for HOMA-IR, BMI and % body fat. We 248 
further explored relationships between baseline sex steroids and individual components of MetS at 249 
follow-up, using linear regression with adjustments for age, centre, alcohol intake, smoking status, 250 
physical activity, general health and the baseline value of the individual component. To meet linear 251 
regression assumptions, glucose and triglyceride levels were log transformed. Results were expressed 252 
as standardised β-coefficients and 95% CI. P<0.05 was considered statistically significant. All 253 
analyses were performed by using STATA version 13 (Stata corp. College station, TX, USA). 254 
 255 
 256 
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Results 257 
Subject characteristics 258 
In EMAS, MetS status at baseline and follow-up could be assessed in 2376 men. Of these men, 725 259 
men with MetS at baseline were excluded from the analysis. 1651 men did not have MetS at baseline. 260 
Of these, 289 (17.5%) developed MetS during the follow-up period.  Baseline characteristics of the 261 
1651 men without baseline MetS are presented in Table 1. Their mean (SD) age was 58.5 (10.7) and 262 
mean BMI was 26.3 kg/m² (3.3). 21.8% of the study subjects used antihypertensive drugs, 8.8% were 263 
on statins and 2.0% were treated for diabetes.  264 
Men with incident MetS had a higher weight, BMI, calculated body fat % and HOMA-IR. They had a 265 
lower baseline self-reported health, compared to the men that did not develop MetS (Table 1). Men 266 
with incident MetS had lower levels of total and free T, a higher E2/T ratio and lower SHBG. Baseline 267 
E2 levels were not significantly different between both groups. Already at baseline, subjects with 268 
incident MetS had a higher waist circumference, systolic and diastolic blood pressure, fasting 269 
triglyceride and glucose levels and lower HDL levels, compared to subject without MetS. Compared 270 
to men who did not develop MetS, those with incident MetS were more often prescribed 271 
antihypertensive drugs, statins and antidiabetic drugs at baseline (Table 1).  272 
 273 
Association between baseline sex steroids and incident MetS  274 
Logistic regression analysis showed that lower total T and free T were associated with an increased 275 
risk of incident MetS (OR=1.64 (CI 1.41-1.90) and OR=1.31 (CI 1.14-1.51) respectively). This 276 
association persisted after adjustment for age, centre and lifestyle factors (alcohol intake, current 277 
smoking status, physical activity and general health) (OR=1.72 (CI 1.48-2.01) for total T and OR=1.36 278 
(CI 1.17-1.59) for free T) and for total T after further adjustment for SHBG (OR=1.43 (CI 1.16-1.76)). 279 
Total E2 levels were not significantly associated with the risk of developing MetS (OR=1.04 (CI 0.91-280 
1.19)). Adding SHBG to the model had no effect on this risk (OR=0.90 (CI 0.78-1.04)). A lower E2/T 281 
ratio was associated with a decreased risk for incident MetS, independent of age, centre and lifestyle 282 
factors and SHBG (OR=0.48 (CI 0.35-0.64)). SHBG itself was also independently associated with 283 
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incident MetS (OR=1.78 (CI 1.48-2.13)). However, after adjustment for total T levels, the association 284 
between SHBG and incident MetS was attenuated, but remained significant (OR=1.33 (CI 1.05-1.68)) 285 
(Figure 1).  286 
Further analysis after categorising sex steroid levels into quintiles, with the middle quintile as referent, 287 
showed no evidence of a threshold effect (data not shown). Adding an interaction term for age (below 288 
or above 60) or for BMI (below or above 30) had no significant effects, indicating that the sex-steroid 289 
associated MetS risk does not vary in different age or BMI groups (data not shown). 290 
 291 
Influence of BMI, body fat and insulin resistance on relation of sex steroids and incident MetS 292 
- Insulin resistance 293 
After further adjustment for HOMA-IR, total T, free T, E2/T ratio and SHBG remained strongly 294 
associated with incident MetS (OR=1.64 (CI 1.40-1.91), OR=1.29 (CI 1.11-1.51), OR=0.41 (CI 0.31-295 
0.54), OR=1.75 (CI 1.45-2.10)). Further the association between total E2 and incident MetS became 296 
borderline significant (OR=1.37 (CI 1.00-1.88), p=0.049)) (Table 2). 297 
 298 
- BMI and percentage body fat  299 
After further adjustment for BMI, the associations between lower total T, free T, E2/T ratio, SHBG 300 
and incident MetS remained significant (OR=1.44 (CI 1.23-1.69), OR=1.24 (CI 1.06-1.45) and 301 
OR=0.60 (CI 0.44-0.81), OR=1.49 (CI 1.23-1.79) respectively). After adjustment for BMI, total E2 302 
was not associated with incident MetS (OR=1.15 (CI 0.99-1.33)). Adjusting for calculated body fat 303 
percentage yielded similar results (Table 2). 304 
 305 
In the Manchester and Leuven cohorts, baseline DXA data are available in 713 men. In this subgroup, 306 
MetS status could be determined in in 595 men at both study phases.  Of these men, 402 (67.6%) had 307 
no MetS at either time point. 59 (9.9%) men developed MetS during the study period.  308 
In this subgroup, lower total T, free T and SHBG were also associated with an increased risk for 309 
incident MetS after adjustment for age, centre and lifestyle factors (OR=2.28 (CI 1.60-3.25), OR=1.90 310 
(CI 1.34-2.69) and OR=1.90 (CI 1.28-2.81) respectively), and a lower E2/T ratio showed an inverse 311 
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association (OR=0.46 (CI 0.27-0.76)). Total E2 was not associated with MetS (OR=1.22 (CI 0.91-312 
1.64)).  313 
For total and free T and SHBG, the association with incident MetS remained after further adjusting for 314 
% body fat (OR=2.25 (CI 1.52-3.31) for total T, OR=1.91 (CI 1.29-2.81) for free T and OR=1.87 (CI 315 
1.23-2.85) for SHBG) or % trunk fat (OR=2.15 (CI 1.45-3.18) for total T, OR=1.85 (CI 1.25-2.74) for 316 
free T and OR=1.78 (CI 1.17-2.71) for SHBG). The E2/T ratio was no longer significantly associated 317 
with MetS after further adjustment for body fat or trunk fat measurements (OR=0.63 (CI 0.35-1.14) 318 
and OR=0.68 (CI 0.37-1.24)). Total E2 was weakly associated with incident MetS when % body fat or 319 
% trunk fat was added to the model (OR=1.49 (CI 1.06-2.10) and OR=1.50 (CI 1.06-2.12)).  320 
 321 
Association between baseline sex steroids and SHBG and MetS components at follow-up 322 
In the unadjusted model, lower total T, free T and SHBG levels at baseline were associated with a 323 
higher waist circumference at follow-up (β= 3.91 (CI 3.47-4.35), β=3.32 (CI 2.86-3.79), β=2.45 (CI 324 
1.97-2.94)) and E2/T ratio was associated with a lower waist circumference (β=-8.01 (CI -8.76—325 
7.26).  However, these associations disappeared after adjustments for age, centre, lifestyle factors and 326 
baseline waist circumference. Similar results were seen for systolic and diastolic blood pressure, 327 
except for the multivariable adjusted association of baseline SHBG and systolic blood pressure at 328 
follow-up (β=1.35 (CI 0.52- 2.17)).  329 
After adjustment for age, centre and lifestyle factors and baseline values of the components, lower 330 
total and free T levels were associated with a higher triglyceride level, lower HDL and higher glucose 331 
levels (β=0.06 (CI 0.04- 0.08), β=-0.04 (CI -0.05- -0.03) and β=0.01 (CI 0.01 - 0.02) for total T and 332 
β=0.04 (CI 0.02- 0.06), β=-0.02 (CI -0.03- -0.01) and β=0.01 (CI 0.0001 - 0.01) for free T). Similar 333 
associations were seen for SHBG. A lower E2/T ratio was associated with lower triglyceride levels, 334 
higher HDL levels and lower glucose levels (β=-0.06 (CI -0.09- -0.03) β=0.05 (CI 0.03-0.07) β=-0.03 335 
(CI -0.04- -0.01)). Lower total E2 levels were only associated with higher triglyceride levels (β=0.02 336 
(CI 0.004 - 0.04)) (Table 3). 337 
 338 
 339 
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Discussion 340 
In this prospective study of middle-aged and elderly men, lower baseline serum T was prospectively 341 
associated with an increased risk for incident MetS. Moreover, the association between low T and 342 
incident MetS persisted after adjustments for SHBG, HOMA-IR, BMI and calculated body fat. In the 343 
Leuven-Manchester subcohort, this association was also independent of DXA-measured body fat and 344 
trunk fat. Total E2 levels were not associated with the development of MetS. A lower E2/T ratio, 345 
reflecting lower aromatisation of T into E2, was associated with a reduced risk of developing MetS. 346 
This association was also independent of SHBG, HOMA-IR and BMI, but not of body fat measured 347 
by DXA. Lower baseline total and free T and SHBG levels were associated with higher triglyceride 348 
and glucose levels and lower HDL levels at follow-up. A lower E2/T ratio was associated with lower 349 
triglyceride and glucose levels and higher HDL levels. Total E2 was only associated with a higher 350 
triglyceride level.  351 
 352 
Similar to the present results, other longitudinal studies such as the Baltimore Longitudinal Study of 353 
Aging (4), the Kuopio Ischemic Heart Disease Risk Factor Study (5) and the Massachusetts Male 354 
Ageing Study (7) showed an increased risk of MetS in men with lower levels of total T or SHBG at 355 
baseline. In contrast, the Framingham Heart Study, the Study of Health in Pomerania and the Concord 356 
Health and Ageing in Men Project, found that only SHBG and not total T was independently 357 
associated with incident MetS (8,9,23). Discrepancies between our findings and other longitudinal 358 
studies could in part be related to differences in the populations studied and the methods used to 359 
measure serum T levels.  360 
Our MetS component data are consistent with other cross-sectional and longitudinal studies, 361 
suggesting that lower baseline total T levels were associated with a less favorable lipid profile (24) and 362 
higher glucose levels (25). 363 
 364 
Previous analysis of baseline EMAS cross-sectional data had revealed that obesity was strongly 365 
associated with low T and low or inappropriately normal LH levels, reflecting dysfunction at the 366 
hypothalamic-pituitary-testicular axis (HPT-axis) and secondary hypogonadism (26). Obesity was also 367 
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associated with a reduced circulating SHBG concentration. Both low SHBG and HPT-axis 368 
dysfunction in obese men may therefore account for the low total T, and both can be induced by 369 
higher levels of proinflammatory cytokines and insulin resistance, associated with adiposity (26,27). 370 
However, adjusting for SHBG and different measures of fat mass as well as insulin resistance did not 371 
affect the association between low T and MetS. This suggests that factors directly associated with low 372 
T may be important in driving the progression to metabolic syndrome in men, independent of SHBG, 373 
insulin resistance and obesity. 374 
However, it remains unclear if low T is a biomarker of an unfavourable metabolic state or a mediating 375 
factor in the development of MetS. Androgen deprivation therapy in prostate cancer patients results in 376 
a higher prevalence of MetS and a higher cardiovascular mortality (28). On the other hand, weight 377 
reduction in obese men increases T levels (29). Testosterone replacement therapy in men with MetS 378 
may improve several MetS components, such as insulin sensitivity, waist circumference and LDL 379 
cholesterol (30). The association between low T and MetS may therefore be bidirectional. 380 
 381 
In contrast to the abundance of data investigating the link between T and MetS, there are few 382 
prospective data investigating the association between E2 and MetS. In men, circulating E2 levels are 383 
in the picomolar range and chromatography/mass spectrometry methods are therefore needed for 384 
accurate measurement of serum E2 (31). Around 60% of circulating E2 in men is produced by 385 
aromatisation of T (11,32). Estrogens play an essential role in male physiology. They are not only 386 
important for bone maintenance, but they also have metabolic effects on carbohydrate and lipid 387 
metabolism and fat distribution, not only in humans, but also in rodents. Estrogen receptor α 388 
disruption, both in the presence or absence of androgen receptor, increases fat mass in male mice 389 
(33,34). An absolute lack of E2, such as in men with congenital aromatase or estrogen receptor alpha 390 
deficiency and in aromatase knockout mice, has also been associated with the development of several 391 
MetS components such as truncal obesity, lipid disorders and insulin resistance (35). Moreover, a 392 
recent study showed that experimentally-induced short-term estrogen deficiency resulted in an 393 
increase in body fat in men (12). In our study, we found no association between baseline E2 levels and 394 
incident MetS. Our results are in line with a cross-sectional study in middle-aged and elderly men (36) 395 
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and a recent longitudinal study in elderly men(23). Only in the latter study E2 was measured by liquid 396 
chromatography-tandem mass spectrometry.  In other recent cross-sectional studies, both higher (37) 397 
and lower (38) E2 levels, measured by radioimmunoassay (which may be unreliable), have been 398 
associated with MetS in men. 399 
The activity of the aromatase enzyme can be upregulated by multiple factors, such as inflammatory 400 
adipocytokines, insulin and free fatty acids. This results in increased intracellular E2 levels that can 401 
activate the estrogen receptor (27,39). Circulating E2 levels may not reflect the local actions of E2 in 402 
target tissues. The E2/T ratio may therefore be a better indicator of aromatisation than a single 403 
measurement of circulating E2. A positive correlation between the E2/T ratio and BMI as well as 404 
different measures of body fat has been reported, but these associations were not independent of 405 
visceral adipose tissue (40). More recently, cross-sectional data from the Boston Area Community 406 
Health/Bone survey also showed a positive association between the E2/T ratio and body composition, 407 
measured anthropometrically and by DXA (13). In a recent short-term intervention study, 408 
administration of an aromatase inhibitor with T replacement to GnRH analog-treated men, thereby 409 
lowering E2/T ratio, resulted in an increase of body fat (12). Interestingly, in our study, a lower E2/T 410 
ratio, reflecting lower aromatisation of T into E2, was strongly associated with a reduced risk for 411 
incident MetS. However, this association was not independent of DXA-measured body fat, indicating 412 
that changes in body composition may modify the association between the estrogen-androgen balance 413 
and MetS. This may account for the discrepancy between our findings and those from short-term 414 
aromatase inhibition. Moreover, administration of an aromatase inhibitor to young men results in 415 
virtually undetectable, non-physiologic E2 levels, which are clearly different from the E2 levels 416 
observed in our study population of middle-aged and older men.  417 
 418 
Our study has several strengths. It is a large, population based study and standardised methods in 419 
design and analysis were used. As recommended by the Endocrine Society (41), serum T and E2 420 
measurements were done by respectively liquid or gas chromatography-tandem mass spectrometry, 421 
giving more accurate results as compared to other population studies that have used immunoassays 422 
(31,42). Furthermore, the prospective design allows insights into the temporal nature of the 423 
16 
 
associations. By adjusting our findings for a range of putative confounding factors, including SHBG, 424 
insulin resistance and body composition, these results add insights into the specific effects of sex 425 
hormones independent of adiposity. 426 
There are some limitations which need to be considered. Our results were based on an analysis of 427 
responders to both baseline and follow up phases and in whom data on MetS were available. Therefore 428 
caution is needed in interpreting data on incidence of MetS. Any response or loss to follow-up bias is 429 
though unlikely to influence our findings as these were based on an internal comparison of responders. 430 
Finally, our data were based on analysis of a relatively healthy proportion of European men. 431 
Extrapolating these data to other populations should be done with care. 432 
 433 
In conclusion, low T but not E2 levels in men may be regarded as a biomarker or risk predictor for 434 
MetS, independently of SHBG, insulin resistance and body composition. A lower E2/T ratio may be 435 
protective against developing MetS. The importance of aromatase activity in MetS requires further 436 
investigation. These findings may have implications for the assessment of cardiometabolic risks in 437 
older and obese men. 438 
 439 
 440 
 441 
 442 
 443 
 444 
 445 
 446 
 447 
 448 
 449 
 450 
 451 
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Figures 640 
Figure 1:  641 
 642 
643 
Associations between decreasing baseline sex steroids and SHBG levels and the development of 644 
metabolic syndrome 645 
Data are reported as standardised odds ratios with 95% confidence intervals for the risk of developing 646 
metabolic syndrome associated with lower baseline sex steroids or SHBG (per 1 SD decrease).  647 
Black circles represent the unadjusted model. White circles represent the multivariable adjusted 648 
model, with adjustments for age, centre, alcohol intake, smoking, physical activity and general health.  649 
Additional adjustments were made for total testosterone (white triangles) or SHBG (black triangles).  650 
*p<0.05; ** p<0.01; *** p<0.001 651 
 652 
 653 
 654 
 655 
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Table 1: Baseline characteristics of study subjects 656 
 
No metabolic syndrome at baseline 
 
No MetS  
at follow-up 
Incident MetS at 
follow-up 
 
 
(n=1651) 
 
(n = 1362, 
82.5%) (n=289, 17.5%) 
 
Physiological measures Mean SD 
 
Mean SD Mean SD 
p-
value 
Age (yr) 58.5 10.7 
 
58.5 10.9 58.6 10.1 0.85 
Height (cm) 174.1 7.1 
 
174.1 7.2 174.4 6.7 0.43 
Weight (kg) 79.9 11.2 
 
78.5 10.6 86.2 11.4 <0.001 
BMI (kg/m
2
) 26.3 3.3 
 
25.9 3.1 28.3 3.3 <0.001 
Calculated body fat (%) 26.6 4.9     26.1 4.8 28.6 4.7 <0.001 
HOMA-IR 2.2 2.5  2.0 1.6 3.1 4.6 <0.001 
Alcohol (five or more 
days/wk) (%) 24.3  
 
25.2  19.7  0.047 
Current smoker (%) 20.6  
 
19.7  24.7  0.055 
Physical activity (time to walk) 
(m/s) 13.1 2.4 
 
13.1 2.3 13.4 2.6 0.07 
General health (fair or poor) 
(%) 25.4  
 
23.4  34.4  <0.001 
 
  
 
     
Hormones   
 
     
Total T (nmol/L) 18.2 6.1 
 
18.7 6.1 16.1 5.5 <0.001 
Free T (pmol/L) 315.6 87.0 
 
319.5 87.7 297.3 81.3 <0.001 
Total E2 (pmol/L) 74.5 25.1 
 
74.7 25.3 73.7 24.2 0.55 
Free E2 (pmol/L) 1.26 0.43 
 
1.26 0.44 1.30 0.42 0.11 
E2/T ratio 0.0043 0.0015 
 
0.0042 0.0014 0.0048 0.0016 <0.001 
SHBG (nmol/L) 45.0 19.4 
 
46.1 19.8 39.8 16.8 <0.001 
        
MetS Components         
Waist circumference (cm) 94.4 9.0  93.1 8.6 100.5 8.3 <0.001 
HDL cholesterol (mmol/L) 1.49 0.37  1.52 0.35 1.36 0.42 <0.001 
Systolic BP (mmHg) 143.0 20.3  142.1 20.1 146.9 21.0 <0.001 
Diastolic BP (mmHg) 85.8 11.7  85.4 11.4 87.9 12.7 0.001 
Fasting triglycerides (mmol/L) 1.24 0.68  1.19 0.65 1.46 0.79 <0.001 
Fasting glucose (mmol/L) 5.29 0.83  5.25 0.79 5.48 0.95 <0.001 
Number of MetS components 1.30 0.68  1.23 0.68 1.67 0.55 <0.001 
         
Medication use         
Using antihypertensive drugs 
(%) 21.8   19.8  31.1  <0.001 
Using statins (%) 8.8   7.9  13.2  0.004 
Using antidiabetic drugs (%) 2.0   1.5  4.2  0.004 
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Table 2: Impact of insulin resistance, BMI and body fat on the association between lower baseline sex steroids and SHBG and incident Metabolic 
syndrome 
 
Data are reported as standardised odds ratios with 95% confidence intervals for the risk of developing metabolic syndrome per standard deviation decrease in baseline sex 
steroids or SHBG. Lifestyle factors: alcohol, current smoking status, physical activity and general health.  
In the complete study sample, insulin resistance (HOMA-IR), BMI or calculated body fat percentage were included in the model. 
In the Manchester and Leuven cohort, DXA measurements of percentage body fat or percentage trunk fat were included in the model. 
*p<0.05; ** p<0.01; *** p<0.001. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Total T Free T E2/T ratio Total E2 SHBG 
Entire study sample       
Adjusted for age, centre and lifestyle factors  1.72 (1.48, 2.01)*** 1.36 (1.17, 1.59)*** 0.38 (0.29, 0.49)*** 1.04 (0.91, 1.19) 1.78 (1.48, 2.13)*** 
       
+ HOMA-IR  1.64 (1.40, 1.91)*** 1.29 (1.11, 1.51)** 0.41 (0.31, 0.54)*** 1.37 (1.00, 1.88)* 1.75 (1.45, 2.10)*** 
+ BMI  1.44 (1.23, 1.69)*** 1.24 (1.06, 1.45)** 0.60 (0.44, 0.81)** 1.15 (0.99, 1.33) 1.49 (1.23, 1.79)*** 
+ Calculated % body fat    1.52 (1.30, 1.79)*** 1.26 (1.08, 1.47)** 0.49 (0.37, 0.66)*** 1.08 (0.94, 1.24) 1.57 (1.31, 1.89)*** 
       
Subgroup analysis in Manchester and Leuven cohorts       
Adjusted for age, centre and  lifestyle factors  2.28 (1.60, 3.25)*** 1.90 (1.34, 2.69)*** 0.46 (0.27, 0.76)** 1.22 (0.91, 1.64) 1.90 (1.28, 2.81)** 
       
+ % Body fat DXA  2.25 (1.52, 3.31)*** 1.91 (1.29, 2.81)** 0.63 (0.35, 1.14) 1.49 (1.06, 2.10)* 1.87 (1.23, 2.85)** 
+ % Trunk fat DXA  2.15 (1.45, 3.18)*** 1.85 (1.25, 2.74)** 0.68 (0.37, 1.24) 1.50 (1.06, 2.12)* 1.78 (1.17, 2.71)** 
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Table 3: Associations between a decrease in baseline sex steroids and SHBG and MetS components at follow up 
 
 
 
Data are reported as β coefficients with 95% confidence interval per standard deviation decrease in baseline sex steroids and SHBG. *p<0.05; ** p<0.01; *** p<0.001 
Model 1: unadjusted. Model 2: adjusted for age, centre, alcohol, current smoking status, physical activity, general health, and baseline value of component 
To meet linear regression assumptions, follow-up triglyceride and glucose levels were log-transformed. A total of 27 outliers with baseline waist circumference <40 cm, 
baseline SHBG >190 nmol/L, baseline E2/T ratio >0.03, follow-up glucose level >12 mmol/L and follow-up triglyceride levels >14 mmol/L were excluded from the analysis. 
Abbreviations: HDL: high density lipoprotein, SBP: systolic blood pressure, DBP: diastolic blood pressure, T: testosterone, E2: estradiol, SHBG: sex hormone binding 
globulin. 
 
 
 
 Follow-up Metabolic syndrome variables 
Baseline 
hormones 
Waist circumference Log triglycerides HDL Log glucose SBP DBP 
Total T       
Model 1 3.91 (3.47, 4.35)*** 0.12 (0.10, 0.14)*** -0.09 (-0.10, -0.07)*** 0.03 (0.02, 0.04)*** 1.75 (0.91, 2.58)*** 0.73 (0.24, 1.21)** 
Model 2 0.08 (-0.15, 0.31) 0.06 (0.04, 0.08)*** -0.04 (-0.05, -0.03)*** 0.01 (0.01, 0.02)*** 0.40 (-0.34, 1.13) -0.05 (-0.48, 0.38) 
       
Free T       
Model 1 3.32 (2.86, 3.79)*** 0.06 (0.04, 0.08)*** -0.04 (-0.05, -0.02)*** 0.03 (0.02, 0.03)*** 1.77 (0.91, 2.62)*** -0.53 (-1.02, -0.03)* 
Model 2 0.19 (-0.05, 0.44) 0.04 (0.02, 0.06)*** -0.02 (-0.03, -0.01)** 0.01 (0.0001, 0.01)* -0.44 (-1.24, 0.36) -0.31 (-0.78, 0.15) 
       
E2/T ratio       
Model 1 -8.01 (-8.76, -7.26)*** -0.16 (-0.19, -0.12)*** 0.13 (0.10, 0.15)*** -0.06 (-0.07, -0.04)*** -4.13 (-5.57, -2.69)** -1.13 (-1.97, -0.29)** 
Model 2 -0.33 (-0.11, 0.76) -0.06 (-0.09, -0.03)** 0.05 (0.03, 0.07)*** -0.03 (-0.04, -0.01)*** 0.17 (-1.14, 1.48) 0.64 (-0.12, 1.41) 
       
Total E2       
Model 1 -0.45 (-0.93, 0.03) 0.06 (0.01, 0.06)** -0.02 (-0.03, 0.00) 0.0003 (-0.008, 0.009) -1.20 (-2.06, -0.35)** -0.14 (-0.64, 0.35) 
Model 2 0.21 (-0.02, 0.43) 0.02 (0.004, 0.04)* -0.01 (-0.02, 0.01) 0.001 (-0.01, 0.01) -0.16 (-0.91, 0.59) -0.06 (-0.51, 0.38) 
       
SHBG       
Model 1 2.45 (1.97, 2.94)*** 0.13 (0.11, 0.15)*** -0.09 (-0.11, -0.07)*** 0.02 (0.01, 0.03)*** 0.84 (-0.03, 1.72) 1.81 (1.31, 2.32)*** 
Model 2 -0.08 (-0.34, 0.17) 0.06 (0.04, 0.08)*** -0.05 (-0.06 -0.03)*** 0.02 (0.01, 0.02)*** 1.35 (0.52, 2.17)** 0.32 (-0.16, 0.81) 
